Alessan­dro Ri­va ex­its top No­var­tis on­col­o­gy post, heads to a trou­bled — but wealthy — Gilead

With its pipeline mired in bad da­ta and se­r­i­al set­backs and an­a­lysts de­mand­ing some sort of co­her­ent strate­gic re­sponse to the omi­nous down­turn in its hep C fran­chise, Gilead $GILD has man­aged to re­cruit one of the top names in on­col­o­gy drug de­vel­op­ment to head up its can­cer R&D ef­forts.

Alessan­dro Ri­va is turn­ing in his Big Phar­ma cre­den­tials at No­var­tis $NVS to move in­to the big biotech, which has tak­en a drub­bing at the hands of dis­ap­point­ed an­a­lysts this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER